A Biobank for the Americas and a Genomics Lab Power Precision Health for All - Seite 3

In addition to sampling from relevant populations, he's also looking to give back to the individuals and communities who contribute to the Biobank of the Americas. Currently, participants who submit their samples can access their own ancestry test results-or they can always opt out of the project if they later change their minds. "It's all part of the right way of doing research, engaging the community, and being really upfront about what we're doing, why we're doing it, and what people can learn," he says. Galatea Bio also offers clinical genetic laboratory-developed tests, including whole-genome sequencing, whole-exome sequencing, and ancestry-adjusted panels for autism, hereditary cancer, immune dysregulation, cardiovascular disease, thyroid disease, and pharmacogenomics.

Bustamante hopes that the biobank Galatea is building can eventually facilitate an exchange of knowledge among investigators, individuals, and communities. Their goal is to have 10 million data points; the biobank currently has about half a million. "We'll be at over a million by the end of this year, and we should be at 10 million by, say, 2026," Bustamante says. "We already have one of the most diverse biobanks in the world. And we're really looking forward to being able to make use of the health care data that's been entrusted to us and do right by the communities we're working with."

Foto: Accesswire

Galatea Bio President and CEO Carlos D. Bustamante, PhD
PHOTO: Josh Ritchie

View additional multimedia and more ESG storytelling from Illumina on 3blmedia.com.

Contact Info:

Spokesperson: Illumina
Website: https://www.3blmedia.com/profiles/illumina
Email: [e-mail]

SOURCE: Illumina

View the original press release on accesswire.com


The Illumina Stock at the time of publication of the news with a raise of +0,02 % to 127,8EUR on Nasdaq stock exchange (18. März 2024, 17:23 Uhr).

So handeln Sie das Kursziel

Der Analyst erwartet ein Kursziel von 109,14$, was einem Rückgang von -4,01% zum aktuellen Kurs entspricht. Mit diesen Produkten können Sie die Kurserwartungen des Analysten übertreffen.

 

Vontobel

 

Alle Partner

Übernehmen

Für Ihre Einstellungen haben wir keine weiteren passenden Produkte gefunden.
Bitte verändern Sie Kursziel, Zeitraum oder Emittent.Alternativ können Sie auch unsere Derivate-Suchen verwenden
Knock-Out-Suche | Optionsschein-Suche | Zertifikate-Suche

WerbungDisclaimer